Natera received a slight analyst price target increase to $260.89 from $259.11, reflecting a 0.7% shift amid mixed revisions after Q4 results and 2026 guidance. The company also announced a landmark oncology data program with 35 studies to be presented at the upcoming ASCO meeting, extending its clinical leadership in precision medicine.